Abstract
Rationale
A growing evidentiary body indicates cannabinoid exposure is conducive to cognitive impairment and psychotic phenomena in vulnerable individuals. In this respect, recent studies have displayed controversial results on the ability of cannabinoids to elicit sensorimotor gating alterations and attentional filtering, whose disruption is a distinctive feature of psychosis.
Objectives
The goal of this study was to investigate the effects of acute, subchronic, and chronic treatment with the synthetic CB receptor agonist WIN 55,212-2 (WIN) on prepulse inhibition (PPI) of the acoustic startle reflex (ASR), a powerful paradigm for evaluation of sensorimotor gating.
Methods
Different groups of adult Sprague-Dawley rats were treated with 0.5, 1, and 2 mg/kg WIN (i.p.) acutely, as well as for 7 days and 21 days. All animals underwent testing 40 min after the last treatment and their evaluation was compared with that of animals treated with vehicle. In a separate group, the effects of WIN withdrawal were also analyzed, 24 h after discontinuation of a 21-day treatment.
Results
No variation in PPI was detected in any of the test groups when compared with controls, whatever the dosage and the treatment.
Conclusions
These findings suggest WIN does not impair sensorimotor gating in Sprague-Dawley rats and confirm clinical evidence according to which cannabis is an unlikely causative of psychosis among non-vulnerable individuals. Nonetheless, since in other studies the same compound was shown to induce PPI alterations in Wistar rats, our results are also suggestive that genetic differences might be critical for the development of cannabis-induced cognitive disorders.
Similar content being viewed by others
References
Acri JB, Brown KJ, Saah MI, Grunberg NE (1995) Strain and age differences in acoustic startle responses and effects of nicotine in rats. Pharmacol Biochem Behav 50:191–198
Ameri A (1999) The effects of cannabinoids on the brain. Prog Neurobiol 58:315–348
Arnold JC, Hunt GE, McGregor IS (2001) Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats. Life Sci 70:97–108
Ashton CH (2001) Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 178:101–106
Bersani G, Orlandi V, Gherardelli S, Pancheri P (2002) Cannabis and neurological soft signs in schizophrenia: absence of relationship and influence on psychopathology. Psychopathology 35:289–295
Bortolato M, Frau R, Aru GN, Orru M, Gessa GL (2004) Baclofen reverses the reduction in prepulse inhibition of the acoustic startle response induced by dizocilpine, but not by apomorphine. Psychopharmacology 171:322–330
Braff DL, Geyer MA (1990) Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 47:181–188
Braff DL, Geyer MA, Swerdlow NR (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156:234–258
Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60:155–163
Chaperon F, Thiebot MH (1999) Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 13:243–281
Chen JP, Paredes W, Lowinson JH, Gardner EL (1991) Strain-specific facilitation of dopamine efflux by delta 9-tetrahydrocannabinol in the nucleus accumbens of rat: an in vivo microdialysis study. Neurosci Lett 129:136–180
Cladel CE, Cho MH, McDonald RD (1966) Effect of amphetamine and catecholamines on startle response and general motor activity of albino rats. Nature 210:864–865
Compton DR, Dewey WL, Martin BR (1990) Cannabis dependence and tolerance production. Adv Alcohol Subst Abuse 9:129–147
Cook SA, Lowe JA, Martin BR (1998) CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 285:1150–1156
Davis M (1979) Diazepam and flurazepam: effects on conditioned fear as measured with the potentiated startle paradigm. Psychopharmacology 62:1–7
Davis M, Gendelman DS, Tischler MD, Gendelman PM (1982) A primary acoustic startle circuit: lesion and stimulation studies. J Neurosci 2:791–805
Degenhardt L, Hall W (2002) Cannabis and psychosis. Curr Psychiatry Rep 4:191–196
Degenhardt L, Hall W, Lynskey M (2003) Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 71:37–48
Devane WA, Dysarz FA III, Johnson MR, Melvin LS, Howlett AC (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605–613
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946–1949
Di Marzo V, Fontana A, Cadas H, chinelli S, Cimino G, Schwartz JC, Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide. Nature 372:686–691
Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ (1991) Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 148:224–230
Egan MF, Weinberger DR (1997) Neurobiology of schizophrenia. Curr Opin Neurobiol 7:701–707
Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, Schilling L, Gigerenzer G, Hoehe MR (1999) Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology 142:295–301
Fried P, Watkinson B, James D, Gray R (2002) Current and former marijuana use: preliminary findings of a longitudinal study of effects on IQ in young adults. CMAJ 166:887–891
Gardner EL, Vorel SR (1998) Cannabinoid transmission and reward-related events. Neurobiol Dis 5:502–533
Geyer MA, Swerdlow NR (1998) Measurement of startle response, prepulse inhibition, and habituation. In: Crawley JN, Skolnick P (eds) Current protocols in neuroscience. Suppl 3, Chapter 8. Wiley, New York, pp 1–15
Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001) Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156:117–154
Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358–363
Glowa JR, Hansen CT (1994) Differences in response to an acoustic startle stimulus among forty-six rat strains. Behav Genet 24:79–84
Graham FK (1975) The more or less startling effects of weak prestimulation. Psychophysiology 12:238–248
Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42:327–360
Harrison GP Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D (2002) Cognitive measures in long-term cannabis users. J Clin Pharmacol 42[Suppl 11]:41S–47S
Herkenham M (1992) Cannabinoid receptor localization in brain: relationship to motor and reward systems. Ann N Y Acad Sci 654:19–32
Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A 87:1932–1936
Herkenham M, Lynn AB, de Costa BR, Richfield EK (1991) Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 547:267–274
Howlett AC (1995) Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 35:607–634
Jones RT, Benowitz NL, Herning RI (1981) Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 21[Suppl 8–9 ]:143S–152S
Keeler MH, Ewing JA, Rouse BA (1971) Hallucinogenic effects of marijuana as currently used. Am J Psychiatry 128:213–216
Koch M (1999) The neurobiology of startle. Prog Neurobiol 59:107–128
Kovasznay B, Bromet E, Schwartz JE, Ram R, Lavelle J, Brandon L (1993) Substance abuse and onset of psychotic illness. Hosp Community Psychiatry 44:567–571
Krystal JH, D’Souza DC, Madonick S, Petrakis IL (1999) Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophr Res 35[Suppl]:S35–S49
Lichtman AH, Martin BR (2002) Marijuana withdrawal syndrome in the animal model. J Clin Pharmacol 42[Suppl 11]:20S–27S
Lyons MJ, Toomey R, Meyer JM, Green AI, Eisen SA, Goldberg J, True WR, Tsuang MT (1997) How do genes influence marijuana use? The role of subjective effects. Addiction 92:409–417
Mailleux P, Vanderhaeghen JJ (1992) Localization of cannabinoid receptor in the human developing and adult basal ganglia. Higher levels in the striatonigral neurons. Neurosci Lett 148:173–176
Maldonado R, Rodriguez de Fonseca F (2002) Cannabinoid addiction: behavioral models and neural correlates. J Neurosci 22:3326–3331
Mansbach RS, Rovetti CC, Winston EN, Lowe JA III (1996) Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology 124:315–322
Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, Johnson MR, Melvin LS, Mechoulam R, Ward SJ (1991) Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40:471–478
Martin RS, Secchi RL, Sung E, Lemaire M, Bonhaus DW, Hedley LR, Lowe DA (2003) Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat. Psychopharmacology 165:128–135
Mendelson JH, Babor TF, Kuehnle JC, Rossi AM, Bernstein JG, Mello NK, Greenberg I (1976) Behavioral and biologic aspects of marijuana use. Ann N Y Acad Sci 282:186–210
Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61–65
Muschamp JW, Siviy SM (2002) Behavioral sensitization to amphetamine follows chronic administration of the CB1 agonist WIN 55,212-2 in Lewis rats. Pharmacol Biochem Behav 73:835–842
Navarro M, Fernandez-Ruiz JJ, de Miguel R, Hernandez ML, Cebeira M, Ramos JA (1993) An acute dose of delta 9-tetrahydrocannabinol affects behavioral and neurochemical indices of mesolimbic dopaminergic activity. Behav Brain Res 57:37–46
Nocerino E, Amato M, Izzo AA (2000) Cannabis and cannabinoid receptors. Fitoterapia 71[Suppl 1]:S6–S12
Palmer SL, Thakur GA, Makriyannis A (2002) Cannabinergic ligands. Chem Phys Lipids 121:3–19
Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129–180
Pertwee RG. (1999) Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6:635–664
Randall MD, Harris D, Kendall DA, Ralevic V (2002) Cardiovascular effects of cannabinoids. Pharmacol Ther 95:191–202
Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264:2511–2518
Rigdon GC (1990) Differential effects of apomorphine on prepulse inhibition of acoustic startle reflex in two rat strain. Psychopharmacology 102:419–421
Rinaldi PC, Thompson RF (1985) Age, sex and strain comparison of habituation of the startle response in the rat. Physiol Behav 35:9–13
Schneider M, Koch M (2002) The cannabinoid agonist WIN 55,212-2 reduces sensorimotor gating and recognition memory in rats. Behav Pharmacol 13:29–37
Schneider M, Koch M (2003) Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 28:1760–1769
Selley DE, Rorrer WK, Breivogel CS, Zimmer AM, Zimmer A, Martin BR, Sim-Selley LJ. (2001) Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G-protein activation. J Neurochem 77:1048–1057
Stanley-Cary CC, Harris C, Martin-Iverson MT (2002) Differing effects of the cannabinoid agonist, CP 55,940, in an alcohol or Tween 80 solvent, on prepulse inhibition of the acoustic startle reflex in the rat. Behav Pharmacol 13:15–28
Sullivan JM (2000) Cellular and molecular mechanisms underlying learning and memory impairments produced by cannabinoids. Learn Mem 7:132–139
Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994) Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51:139–154
Swerdlow NR, Varty GB, Geyer MA (1998) Discrepant findings of clozapine effects on prepulse inhibition of startle: is it the route or the rat? Neuropsychopharmacology 18:50–56
Swerdlow NR, Braff DL, Geyer MA (2000) Animal models of sensorimotor gating: what we know, what we think we know, and what we hope we know soon. Behav Pharmacol 11:185–204
Wecker JR, Ison JR (1986) Effects of motor activity on the elicitation and modification of the startle reflex in rats. Anim Learn Behav 14:287–292
Wiesbeck GA, Schuckit MA, Kalmijn JA, Tipp JE, Bucholz KK, Smith TL (1996) An evaluation of the history of a marijuana withdrawal syndrome in a large population. Addiction 91:1469–1478
Acknowledgements
We are indebted to Alberto Casti, for his precious technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bortolato, M., Aru, G.N., Frau, R. et al. The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. Psychopharmacology 177, 264–271 (2005). https://doi.org/10.1007/s00213-004-1941-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-004-1941-4